08:28 AM EDT, 06/05/2024 (MT Newswires) -- Avinger (AVGR) said Wednesday that it has trimmed its peripheral business headcount by 33% to enhance focus on its coronary artery disease program.

The job cuts are expected to generate significant cost savings in the second half of this year, Avinger said.

The company said it remains on track to file an investigational device exemption application at the US Food and Drug Administration later this year.